Daewon Pharm (003220) - Net Assets

Latest as of December 2025: ₩274.58 Billion KRW ≈ $186.08 Million USD

Based on the latest financial reports, Daewon Pharm (003220) has net assets worth ₩274.58 Billion KRW (≈ $186.08 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩613.65 Billion ≈ $415.86 Million USD) and total liabilities (₩339.07 Billion ≈ $229.78 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 003220 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩274.58 Billion
% of Total Assets	44.75%
Annual Growth Rate	7.19%
5-Year Change	25.72%
10-Year Change	69.48%
Growth Volatility	4.21

Daewon Pharm - Net Assets Trend (2011–2025)

This chart illustrates how Daewon Pharm's net assets have evolved over time, based on quarterly financial data. See 003220 days of operational coverage to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Daewon Pharm (2011–2025)

The table below shows the annual net assets of Daewon Pharm from 2011 to 2025. For live valuation and market cap data, see Daewon Pharm market capitalisation.

Year	Net Assets	Change
2025-12-31	₩274.58 Billion ≈ $186.08 Million	-3.51%
2024-12-31	₩284.58 Billion ≈ $192.85 Million	+7.69%
2023-12-31	₩264.26 Billion ≈ $179.09 Million	+6.23%
2022-12-31	₩248.77 Billion ≈ $168.58 Million	+13.90%
2021-12-31	₩218.40 Billion ≈ $148.01 Million	+2.65%
2020-12-31	₩212.77 Billion ≈ $144.19 Million	+4.19%
2019-12-31	₩204.22 Billion ≈ $138.39 Million	+11.47%
2018-12-31	₩183.20 Billion ≈ $124.15 Million	+8.96%
2017-12-31	₩168.13 Billion ≈ $113.94 Million	+3.78%
2016-12-31	₩162.01 Billion ≈ $109.79 Million	+8.98%
2015-12-31	₩148.66 Billion ≈ $100.75 Million	+10.52%
2014-12-31	₩134.51 Billion ≈ $91.16 Million	+9.14%
2013-12-31	₩123.25 Billion ≈ $83.53 Million	+9.14%
2012-12-31	₩112.92 Billion ≈ $76.53 Million	+8.67%
2011-12-31	₩103.92 Billion ≈ $70.42 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Daewon Pharm's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 25140664812000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	₩251.41 Billion	94.54%
Other Components	₩14.51 Billion	5.46%
Total Equity	₩265.92 Billion	100.00%

Daewon Pharm Competitors by Market Cap

The table below lists competitors of Daewon Pharm ranked by their market capitalization.

Company	Market Cap
Laxmi Goldorna House Ltd NSE:LGHL	$124.14 Million
BICO Group AB ST:BICO	$124.14 Million
Jindal Poly Investment and Finance Company Limited NSE:JPOLYINVST	$124.14 Million
Shaver Shop Group Ltd AU:SSG	$124.22 Million
TONGDAO LIEP.GR. DL-0001 F:6WT	$124.01 Million
Siam Wellness Group Public Company Limited BK:SPA	$123.92 Million
Seoyon Co Ltd KO:007860	$123.86 Million
DIO Corporation KQ:039840	$123.85 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Daewon Pharm's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 275,284,566,430 to 265,918,340,220, a change of -9,366,226,210 (-3.4%).
Net loss of 1,379,677,420 reduced equity.
Dividend payments of 6,430,031,700 reduced retained earnings.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	₩-1.38 Billion	-0.52%
Dividends Paid	₩6.43 Billion	-2.42%
Other Changes	₩-1.56 Billion	-0.59%
Total Change	₩-	-3.40%

Book Value vs Market Value Analysis

This analysis compares Daewon Pharm's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.69x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has decreased from 1.06x to 0.69x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	₩8019.68	₩8540.00	x
2018-12-31	₩8761.74	₩8540.00	x
2019-12-31	₩9785.93	₩8540.00	x
2020-12-31	₩10382.50	₩8540.00	x
2021-12-31	₩10335.27	₩8540.00	x
2022-12-31	₩11966.66	₩8540.00	x
2023-12-31	₩12558.89	₩8540.00	x
2024-12-31	₩12843.70	₩8540.00	x
2025-12-31	₩12406.70	₩8540.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Daewon Pharm utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -0.52%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -0.23%
• Asset Turnover: 0.99x
• Equity Multiplier: 2.31x
Recent ROE (-0.52%) is below the historical average (8.96%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2011	9.10%	6.79%	0.99x	1.35x	₩-937.14 Million
2012	8.55%	6.96%	0.94x	1.31x	₩-1.62 Billion
2013	10.06%	7.75%	0.99x	1.31x	₩69.83 Million
2014	11.75%	8.64%	1.01x	1.35x	₩2.34 Billion
2015	11.94%	8.19%	1.11x	1.31x	₩2.88 Billion
2016	12.54%	8.41%	1.12x	1.33x	₩4.10 Billion
2017	6.39%	4.05%	1.17x	1.35x	₩-6.06 Billion
2018	12.94%	8.28%	1.04x	1.50x	₩5.39 Billion
2019	13.32%	8.59%	0.97x	1.60x	₩6.79 Billion
2020	8.25%	5.72%	0.92x	1.57x	₩-3.75 Billion
2021	3.19%	1.97%	0.82x	1.96x	₩-14.94 Billion
2022	12.73%	6.67%	1.06x	1.81x	₩6.85 Billion
2023	8.98%	4.54%	1.04x	1.91x	₩-2.70 Billion
2024	5.16%	2.38%	1.03x	2.12x	₩-13.32 Billion
2025	-0.52%	-0.23%	0.99x	2.31x	₩-27.97 Billion

Industry Comparison

This section compares Daewon Pharm's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $413,268,404,689
Average return on equity (ROE) among peers: 2.07%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Daewon Pharm (003220)	₩274.58 Billion	9.10%	1.23x	$124.04 Million
Dongwha Pharm.Co.Ltd (000020)	$360.13 Billion	4.96%	0.24x	$95.42 Million
Yuhan Corp. (000100)	$592.86 Billion	10.31%	0.52x	$3.80 Billion
Yuhan Corp Preferred (000105)	$1.94 Trillion	5.30%	0.27x	$49.81 Million
Yuyu Pharma (000220)	$69.50 Billion	3.97%	0.28x	$42.61 Million
Yuyu Pharma Inc (000225)	$90.54 Billion	5.22%	0.52x	$14.28 Million
Yuyu Pharma Inc (000227)	$135.06 Billion	6.46%	0.54x	$41.70 Million
Ildong Holdings Co Ltd (000230)	$169.90 Billion	-35.07%	4.16x	$51.96 Million
Samil Pharm (000520)	$63.55 Billion	2.11%	2.02x	$99.41 Million
Donga Socio Holdings (000640)	$602.64 Billion	7.95%	1.03x	$347.30 Million
Jw Pharmac (001060)	$112.60 Billion	9.51%	2.66x	$408.02 Million

About Daewon Pharm

KO:003220 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$124.04 Million

₩183.04 Billion KRW

Market Cap Rank

#18454 Global

#829 in Korea

Share Price

₩8540.00

Change (1 day)

-2.95%

52-Week Range

₩8220.00 - ₩13600.00

All Time High

₩23535.34